{
    "organizations": [],
    "uuid": "b708842ac4bcd1f474db74650683944e8b5d1af5",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-sanbio-and-teijin-to-terminate-lic/brief-sanbio-and-teijin-to-terminate-licensing-agreement-regarding-sb623-for-stroke-treatment-idUSL4N1Q43QZ",
    "ord_in_thread": 0,
    "title": "BRIEF-SanBio and Teijin to terminate licensing agreement regarding SB623 for stroke treatment",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 14 (Reuters) - SanBio Co Ltd\n* Says co and Teijin Limited would terminate the exclusive licensing agreement signed in 2009, regarding the development and marketing of SB623 for stroke treatment in Japan\nSource text in Japanese: goo.gl/1xt25t\nFurther company coverage: (Beijing Headline News)\n ",
    "published": "2018-02-14T17:16:00.000+02:00",
    "crawled": "2018-02-15T20:28:06.013+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "sanbio",
        "co",
        "ltd",
        "say",
        "co",
        "teijin",
        "limited",
        "would",
        "terminate",
        "exclusive",
        "licensing",
        "agreement",
        "signed",
        "regarding",
        "development",
        "marketing",
        "sb623",
        "stroke",
        "treatment",
        "japan",
        "source",
        "text",
        "japanese",
        "company",
        "coverage",
        "beijing",
        "headline",
        "news"
    ]
}